Sign In
Buy ESPR
$3.14
+0 (+0%)
At Close: Jun 03, 2026
Esperion Therapeutics (NASDAQ:ESPR) Stock Price Down 6.7%
09:10am, Sunday, 05'th Apr 2020
Shares of Esperion Therapeutics Inc (NASDAQ:ESPR) traded down 6.7% during mid-day trading on Friday . The company traded as low as $29.90 and last traded at $30.76, 685,347 shares changed hands during
Esperion participates in a conference call with Credit Suisse ESPR
09:13am, Saturday, 04'th Apr 2020
Esperion participates in a conference call with Credit Suisse ESPR
Analysts Anticipate Esperion Therapeutics Inc (NASDAQ:ESPR) Will Announce Quarterly Sales of $960,000.00
08:34am, Saturday, 04'th Apr 2020
Analysts expect Esperion Therapeutics Inc (NASDAQ:ESPR) to post sales of $960,000.00 for the current fiscal quarter, Zacks Investment Research reports. Two analysts have issued estimates for Esperion
Esperion Therapeutics (NASDAQ:ESPR) Cut to "Sell" at BidaskClub
06:52am, Saturday, 04'th Apr 2020
BidaskClub lowered shares of Esperion Therapeutics (NASDAQ:ESPR) from a hold rating to a sell rating in a research note published on Tuesday morning, BidAskClub reports. Other analysts have also recen
Esperion Therapeutics (NASDAQ:ESPR) Earns Buy Rating from Needham & Company LLC
10:22am, Friday, 03'rd Apr 2020
Needham & Company LLC restated their buy rating on shares of Esperion Therapeutics (NASDAQ:ESPR) in a research report report published on Tuesday morning, TipRanks reports. They currently have a $158.
Esperion Therapeutics Inc (NASDAQ:ESPR) Shares Purchased by Baird Financial Group Inc.
09:38am, Friday, 03'rd Apr 2020
Baird Financial Group Inc. boosted its stake in Esperion Therapeutics Inc (NASDAQ:ESPR) by 1.6% during the 4th quarter, HoldingsChannel reports. The fund owned 18,829 shares of the biopharmaceutical c
-$3.23 Earnings Per Share Expected for Esperion Therapeutics Inc (NASDAQ:ESPR) This Quarter
09:12am, Thursday, 02'nd Apr 2020
Equities analysts expect Esperion Therapeutics Inc (NASDAQ:ESPR) to report ($3.23) earnings per share (EPS) for the current fiscal quarter, according to Zacks. Two analysts have provided estimates for
Oppenheimer sees 26% downside in Intuitive Surgical in premarket action
11:51am, Wednesday, 01'st Apr 2020
Apellis Pharmaceuticals (NASDAQ:APLS) initiated with Strong Buy rating and $86 (221% upside) price target at Raymond James.BioXcel Therapeutics (NASDAQ:BTAI) initiated with Buy rating and $45 (101% up
Esperion initiated with a Buy at BofA ESPR
11:06am, Wednesday, 01'st Apr 2020
Esperion initiated with a Buy at BofA BofA ESPR
B of A Securities Initiates Coverage On Esperion Therapeutics with Buy Rating, Announces Price Target to $50
12:00am, Wednesday, 01'st Apr 2020Needham Sticks to Its Buy Rating for Esperion (ESPR)
03:21pm, Tuesday, 31'st Mar 2020
In a report released today, Chad Messer from Needham reiterated a Buy rating on Esperion (ESPR), with a price target of $158.00. The company's shares
Needham Sticks to Its Buy Rating for Esperion (ESPR)
03:21pm, Tuesday, 31'st Mar 2020
In a report released today, Chad Messer from Needham reiterated a Buy rating on Esperion (ESPR – Research Report), with
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech stocks that hit 52-week highs March 30.)
Athersys Inc (NASDAQ:...
Axa Invests $4.91 Million in Esperion Therapeutics Inc (NASDAQ:ESPR)
11:28am, Tuesday, 31'st Mar 2020
Axa purchased a new position in Esperion Therapeutics Inc (NASDAQ:ESPR) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commissi
Esperion (ESPR) announced today that NEXLETOL™ (bempedoic acid) tablet, an oral, once-daily, non-statin LDL-Cholesterol (LDL-C) lowering medicine is now available in U.S. pharmacies. Esperion is c
